Vascular endothelial growth factor serum levels in pregnancy and preeclampsia
Vascular endothelial growth factor serum levels in pregnancy and preeclampsia
复制标题
DOI:
10.1034/j.1600-0412.2000.079001077.x
复制
发表时间:
2000-01-01
影响因子:
4.3
通讯作者:
Tempfer, C
中科院分区:
文献类型:
--
作者:
Hefler, L;Obermair, A;Tempfer, C
Preeclampsia (PE) is one of the most common medical complications of pregnancy and an important cause of maternal and perinatal morbidity and mortality worldwide. Despite the clinical importance of PE, the pathophysiological mechanisms of this disease remain to be elucidated. It has been speculated that vascular endothelial growth factor (VEGF), by causing endothelial cell alteration, is involved in the natural history of PE (1, 2). The role of VEGF serum levels in pregnancy and PE, however, has been discussed controversially. Baker et al. reported that VEGF serum levels are elevated in women with PE compared to healthy pregnant women (1). In contrast, Lyall et al. demonstrated that VEGF serum levels are reduced in healthy pregnant women compared to healthy non-pregnant women, and are further reduced in women with PE (3). Anthony et al., however, showed that VEGF serum levels are increased in healthy pregnant women compared to healthy non-pregnant women (4). The aim of the present study was to evaluate VEGF serum levels in 46 women with PE and 46 healthy pregnant women, matched for age and parity with respect to the clinical usefulness of this serum marker as differentiation and prognostic marker of PE. Furthermore, VEGF serum levels were determined in a panel of 130 healthy nonpregnant women. For the measurement of serumAbbreviations: